Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'METASTATIC COLORECTAL-CANCER' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 176 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Shah, MA; Schwartz, GK
      Cell cycle-mediated drug resistance: An emerging concept in cancer therapy

      CLINICAL CANCER RESEARCH
    2. Maliepaard, M; van Gastelen, MA; Tohgo, A; Hausheer, FH; van Waardenburg, RCAM; de Jong, LA; Pluim, D; Beijnen, JH; Schellens, JHM
      Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918

      CLINICAL CANCER RESEARCH
    3. Minami, H; Fujii, H; Igarashi, T; Itoh, K; Tamanoi, K; Oguma, T; Sasaki, Y
      Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks

      CLINICAL CANCER RESEARCH
    4. Fortner, JG; Blumgart, LH
      A historic perspective of liver surgery for tumors at the end of the millennium

      JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    5. Jarnagin, WR; Bach, AM; Winston, CB; Hann, LE; Heffernan, N; Loumeau, T; DeMatteo, RP; Fong, Y; Blumgart, LH
      What is the yield of intraoperative ultrasonography during partial hepatectomy for malignant disease?

      JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    6. Launois, R; Portafax, C; Le Lay, K; Megnigbeto, A; Perrocheau, G
      Internet pharmaco-economic studies in metastatic colorectal cancer

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    7. Maindrault-Goebel, F; de Gramont, A; Louvet, C; Andre, T; Carola, E; Mabro, M; Artru, P; Gilles, V; Lotz, JP; Izrael, V; Krulik, M
      High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)

      EUROPEAN JOURNAL OF CANCER
    8. Cavaletti, G; Tredici, G; Petruccioli, MG; Donde, E; Tredici, P; Marmiroli, P; Minoia, C; Ronchi, A; Bayssas, M; Etienne, GG
      Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat

      EUROPEAN JOURNAL OF CANCER
    9. Guichard, S; Arnould, S; Hennebelle, I; Bugat, R; Canal, P
      Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo

      ANTI-CANCER DRUGS
    10. Ong, SYK; Clarke, SJ; Bishop, J; Dodds, HM; Rivory, LP
      Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction

      ANTI-CANCER DRUGS
    11. Rosati, G; Rossi, A; Tucci, A; Pizza, C; Manzione, L
      Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer

      ANNALS OF ONCOLOGY
    12. Sanz-Altamira, PM; O'Reilly, E; Stuart, KE; Raeburn, L; Steger, C; Kemeny, NE; Saltz, LB
      A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma

      ANNALS OF ONCOLOGY
    13. Blanke, CD; Haller, DG; Benson, AB; Rothenberg, ML; Berlin, J; Mori, M; Hsieh, YC; Miller, LL
      A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma

      ANNALS OF ONCOLOGY
    14. Rothenberg, ML; Kuhn, JG; Schaaf, LJ; Rodriguez, GI; Eckhardt, SG; Villalona-Calero, MA; Rinaldi, DA; Hammond, LA; Hodges, S; Sharma, A; Elfring, GL; Petit, RG; Locker, PK; Miller, LL; von Hoff, DD
      Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks

      ANNALS OF ONCOLOGY
    15. Cascinu, S; Labianca, R; Daniele, B; Beretta, G; Salvagni, S
      Survival and quality of life in gastrointestinal tumors: Two different endpoints?

      ANNALS OF ONCOLOGY
    16. Shimizu, M; Tamura, T; Yamada, Y; Akiyama, Y; Saijo, N; Nishio, K
      CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNAin mouse liver

      JAPANESE JOURNAL OF CANCER RESEARCH
    17. Rosell, R; Sanchez, JM; Taron, M; O'Brate, A; Gutierrez, JL; Monzo, M; Felip, E; Sanchez, JJ; Alberola, V
      Novel approaches in the treatment of non-small-cell lung cancer

      ONCOLOGY-NEW YORK
    18. Rich, TA; Kirichenko, AV
      Camptothecin schedule and timing of administration with irradiation

      ONCOLOGY-NEW YORK
    19. Royce, ME; Hoff, PM; Dumas, P; Lassere, Y; Lee, JJ; Coyle, J; Ducharme, MP; De Jager, R; Pazdur, R
      Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): A novelcamptothecin analog

      JOURNAL OF CLINICAL ONCOLOGY
    20. Stevenson, JP; Redlinger, M; Kluijtmans, LAJ; Sun, WJ; Algazy, K; Giantonio, B; Haller, DG; Hardy, C; Whitehead, AS; O'Dwyer, PJ
      Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer

      JOURNAL OF CLINICAL ONCOLOGY
    21. Rothenberg, ML; Meropol, NJ; Poplin, EA; Van Cutsem, E; Wadler, S
      Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel

      JOURNAL OF CLINICAL ONCOLOGY
    22. Hartung, G
      New developments in chemotherapy of gastrointestinal carcinomas

      ONKOLOGIE
    23. Sitzung, Z; Benson, AB; Goldberg, RM
      Oxaliplatin (Eloxatin) - Advances in cancer therapy 2001 - Introduction

      ONKOLOGIE
    24. Hector, S; Bolanowska-Higdon, W; Zdanowicz, J; Hitt, S; Pendyala, L
      In vitro studies on the mechanisms of oxaliplatin resistance

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    25. Aschele, C; Sartor, L; Lonardi, S; Friso, M; Monfardini, S
      Oxaliplatin in rectal cancer. Clinical aspects: The medical oncologist point of view

      TUMORI
    26. Lokich, J
      Phase I clinical trial of weekly combined topotecan and irinotecan

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    27. Gil-Delgado, MA; Antoine, EC; Guinet, F; Bassot, V; Grapin, JP; Benhammonda, A; Adam, R; Castaing, D; Bismuth, H; Khayat, D
      Phase I-II study of irinotecan in combination with mitomycin C in patientswith advanced gastrointestinal cancer

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    28. Lima, CMSR; Urbanic, JJ; Lal, A; Kneuper-Hall, R; Brunson, CY; Green, MR
      Beyond pancreatic cancer: Irinotecan and gemcitabine in solid tumors and hematologic malignancies

      SEMINARS IN ONCOLOGY
    29. O'Connell, MJ
      North Central Cancer Treatment Group-Mayo Clinic trials in colon cancer

      SEMINARS IN ONCOLOGY
    30. Hanioka, N; Ozawa, S; Jinno, H; Ando, M; Saito, Y; Sawada, J
      Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin

      XENOBIOTICA
    31. Moroz, P; Jones, SK; Winter, J; Gray, BN
      Targeting liver tumors with hyperthermia: Ferromagnetic embolization in a rabbit liver tumor model

      JOURNAL OF SURGICAL ONCOLOGY
    32. Pavlinkova, G; Colcher, D; Booth, BJM; Goel, A; Wittel, UA; Batra, SK
      Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs

      INTERNATIONAL JOURNAL OF CANCER
    33. Takeda, Y; Kobayashi, K; Akiyama, Y; Soma, T; Handa, S; Kudoh, S; Kudo, K
      Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients

      INTERNATIONAL JOURNAL OF CANCER
    34. Marchenay, C; Cellarier, E; Levi, F; Rolhion, C; Kwiatkowski, F; Claustrat, B; Madelmont, JC; Chollet, P
      Circadian variation in O-6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects

      INTERNATIONAL JOURNAL OF CANCER
    35. Johnson, K; Bakhsh, A; Young, D; Martin, E; Arnold, M
      Correlating computed tomography and positron emission tomography scan withoperative findings in metastatic colorectal cancer

      DISEASES OF THE COLON & RECTUM
    36. Scheele, J
      Anatomical and atypical liver resection

      CHIRURG
    37. Granda, TG; Filipski, E; D'Attino, RM; Vrignaud, P; Anjo, A; Bissery, MC; Levi, F
      Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination

      CANCER RESEARCH
    38. Evrard, S
      Towards the redefinition of the aims of palliative surgery?

      BULLETIN DU CANCER
    39. Boige, V; Ducreux, M
      Prevention and treatment of chemotherapy-induced digestive toxicities

      BULLETIN DU CANCER
    40. Laadem, A; Cvitkovic, E
      Oxaliplatin: a first DACH-platinum in oncology

      BULLETIN DU CANCER
    41. Raymond, E; Faivre, S; Coudray, AM; Louvet, C; Gespach, C
      Preclinical studies of oxaliplatin in combination chemotherapy

      BULLETIN DU CANCER
    42. Goldwasser, F; Misset, JL
      Clinical use of oxaliplatin in solid tumors

      BULLETIN DU CANCER
    43. Fischel, JL; Rostagno, P; Formento, P; Dubreuil, A; Etienne, MC; Milano, G
      Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines

      BRITISH JOURNAL OF CANCER
    44. Kemeny, MM
      The surgical aspects of the totally implantable hepatic artery infusion pump

      ARCHIVES OF SURGERY
    45. Johnson, PJ
      Systemic chemotherapy of liver tumors

      SEMINARS IN SURGICAL ONCOLOGY
    46. Mermershtain, W; Lavrenkov, K; Cohen, Y
      Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer

      JOURNAL OF CHEMOTHERAPY
    47. Kehrer, DFS; Yamamoto, W; Verweij, J; de Jonge, MJA; de Bruijn, P; Sparreboom, A
      Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies

      CLINICAL CANCER RESEARCH
    48. Pitot, HC; Goldberg, RM; Reid, JM; Sloan, JA; Skaff, PA; Erlichman, C; Rubin, J; Burch, PA; Adjei, AA; Alberts, SA; Schaaf, LJ; Elfring, G; Miller, LL
      Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy

      CLINICAL CANCER RESEARCH
    49. Graham, MA; Lockwood, GF; Greenslade, D; Brienza, S; Bayssas, M; Gamelin, E
      Clinical pharmacokinetics of oxaliplatin: A critical review

      CLINICAL CANCER RESEARCH
    50. van Groeningen, CJ; Van der Vijgh, WJF; Baars, JJ; Stieltjes, H; Huibregtse, K; Pinedo, HM
      Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: A need for guidelines

      CLINICAL CANCER RESEARCH
    51. Lechner, P; Lind, P; Goldenberg, DM
      Can postoperative surveillance with serial CEA immunoscintigraphy detect resectable rectal cancer recurrence and potentially improve tumor-free survival?

      JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    52. Misset, JL; Bleiberg, H; Sutherland, W; Bekradda, M; Cvitkovic, E
      Oxaliplatin clinical activity: a review

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    53. Saga, Y; Suzuki, M; Sato, I; Shirasaka, T
      An in vitro examination of a 5-fluorouracil regimen involving 'intermittent' continuous venous infusion using cultured cell lines derived from ovarian cancers

      ONCOLOGY REPORTS
    54. Verweij, J; de Jonge, MJA
      Achievements and future of chemotherapy

      EUROPEAN JOURNAL OF CANCER
    55. Madarnas, Y; Webster, P; Shorter, AM; Bjarnason, GA
      Irinotecan-associated pulmonary toxicity

      ANTI-CANCER DRUGS
    56. Hennebelle, I; Terret, C; Chatelut, E; Bugat, R; Canal, P; Guichard, S
      Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitra-phenylacetate converting carboxylesterase activity

      ANTI-CANCER DRUGS
    57. van Riel, JMGH; van Groeningen, CJ
      Palliative chemotherapy in advanced gastrointestinal cancer

      EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
    58. Kaneki, T; Koizumi, T; Kawashima, A; Tsushima, K; Kubo, K; Fujimoto, K; Honda, T; Akamatsu, T
      Double cancer (lung and colon cancer) that showed complete remission with irinotecan and cisplatin combined chemotherapy

      JOURNAL OF GASTROENTEROLOGY
    59. Punt, CJA
      'Hold the Mayo': Solid facts or pulp fiction?

      ANNALS OF ONCOLOGY
    60. Goldwasser, F; Gross-Goupil, M; Tigaud, JM; Di Palma, M; Marceau-Suissa, J; Wasserman, E; Yovine, A; Misset, JL; Cvitkovic, E
      Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients

      ANNALS OF ONCOLOGY
    61. Saltz, L
      Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer

      ONCOLOGY-NEW YORK
    62. Mitchell, EP
      Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer

      ONCOLOGY-NEW YORK
    63. Ribrag, V; Raymond, E
      The concept of time in delivering a medication: the case of anticancer agents

      M S-MEDECINE SCIENCES
    64. Schraub, S; Mercier, M; Arveux, P
      Quality of life assessment in cancerology

      PRESSE MEDICALE
    65. Dawson, LA; McGinn, CJ; Normolle, D; Ten Haken, RK; Walker, S; Ensminger, W; Lawrence, TS
      Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies

      JOURNAL OF CLINICAL ONCOLOGY
    66. de Jonge, MJA; Sparreboom, A; Planting, AST; van der Burg, MEL; de Boer-Dennert, MM; ter Steeg, J; Jacques, C; Verweij, J
      Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors

      JOURNAL OF CLINICAL ONCOLOGY
    67. Lin, JK; Wang, WS; Hsieh, RK; Hsu, TC; Chiou, TJ; Liu, JH; Fan, FS; Yen, CC; Lin, TC; Jiang, JK; Yang, SH; Wang, HS; Chen, PM
      Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience

      JAPANESE JOURNAL OF CLINICAL ONCOLOGY
    68. Clarke, SJ; Beale, PJ; Rivory, LP
      Clinical and preclinical pharmacokinetics of raltitrexed

      CLINICAL PHARMACOKINETICS
    69. Rousseau, A; Marquet, P; Debord, J; Sabot, C; Lachatre, G
      Adaptive control methods for the dose individualisation of anticancer agents

      CLINICAL PHARMACOKINETICS
    70. Levi, F; Metzger, G; Massari, C; Milano, G
      Oxaliplatin - Pharmacokinetics and chronopharmacological aspects

      CLINICAL PHARMACOKINETICS
    71. Dogliotti, L; Garufi, C; Iacobelli, S
      Chronochemotherapy

      TUMORI
    72. Mavligit, GM; Estrov, Z
      CA 125: A clinically useful tumor marker in the management of colorectal carcinoma metastatic to the liver in patients with normal carcinoembryonic antigen

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    73. Cure, H; Chevalier, V; Pezet, D; Bousquet, J; Focan, C; Levi, F; Garufi, C; Chipponi, J; Chollet, P
      Phase II trial of chronomodulated infusion of 5-fluorouracil and folinic acid in metastatic colorectal cancer

      ANTICANCER RESEARCH
    74. Umezawa, T; Kiba, T; Numata, K; Saito, T; Nakaoka, M; Shintani, S; Sekihara, H
      Comparisons of the pharmacokinetics and the leukopenia and thrombocytopenia grade after administration of irinotecan and 5-fluorouracil in combination to rats

      ANTICANCER RESEARCH
    75. Hartmann, JT; Kanz, L; Bokemeyer, C
      Phase II study of continuous 120-hour- infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma

      ANTICANCER RESEARCH
    76. Potamianos, S; Varvarigou, AD; Archimandritis, SC
      Radioimmunoscintigraphy and radioimmunotherapy in cancer: Principles and application

      ANTICANCER RESEARCH
    77. Kleeberg, UR
      Plasma and salivary pharmacokinetics of 5-Fluorouracil

      STRAHLENTHERAPIE UND ONKOLOGIE
    78. Wang, WS; Lin, JK; Chiou, TJ; Liu, JH; Fan, FS; Yen, CC; Lin, TC; Jiang, JK; Yang, SH; Chen, PM
      Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer

      HEPATO-GASTROENTEROLOGY
    79. Rodriguez-Galindo, C; Radomski, K; Stewart, CF; Furman, W; Santana, VM; Houghton, PJ
      Clinical use of topoisomerase I inhibitors in anticancer treatment

      MEDICAL AND PEDIATRIC ONCOLOGY
    80. Misset, JL; Levi, F
      Chronotherapy with 5-fluorouracil and other drugs in gastrointestinal malignancies

      SEMINARS IN ONCOLOGY
    81. Buell, JF; Rosen, S; Yoshida, A; Labow, D; Limsrichamrern, S; Cronin, DC; Bruce, DS; Wen, M; Michelassi, F; Millis, JM; Posner, MC
      Hepatic resection: Effective treatment for primary and secondary tumors

      SURGERY
    82. Heideman, DAM; Gerritsen, WR; Craanen, ME
      Gene therapy for gastrointestinal tract cancer: a review

      SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
    83. Chiche, L
      What's new in liver surgery?

      JOURNAL DE CHIRURGIE
    84. Graeven, U; Schmiegel, W
      Colon cancer - Consensus of therapeutic strategies

      INTERNIST
    85. Avital, S; Haddad, R; Troitsa, A; Kashtan, H; Brazovsky, E; Gitstein, G; Skornick, Y; Schneebaum, S
      Radioimmunoguided surgery for recurrent colorectal cancer manifested by isolated CEA elevation

      CANCER
    86. Ychou, M; Senesse, P; Quenet, F
      Update on gastroenterology

      BULLETIN DU CANCER
    87. Adam, R; Laurent, A; Azoulay, D; Castaing, D; Bismuth, H
      Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors

      ANNALS OF SURGERY
    88. Rahusen, FD; Cuesta, MA; Meijer, S
      Untitled - Reply

      ANNALS OF SURGERY
    89. Ellenberg, SS; Temple, R
      Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 2: Practical issues and specific cases

      ANNALS OF INTERNAL MEDICINE
    90. Rucker, R; Bresler, HS; Heffelfinger, M; Kim, JA; Martin, EW; Triozzi, PL
      Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer

      JOURNAL OF IMMUNOTHERAPY
    91. van Zanten-Przybysz, I; Molthoff, CFM; Visser, GWM; Verheijen, RMH; Plaizier, MABD; Pijpers, R; Kenemans, P; Roos, JC
      I-131-labelled chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study

      TUMOR TARGETING
    92. Zeghari-Squalli, N; Raymond, E; Cvitkovic, E; Goldwasser, F
      Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin

      CLINICAL CANCER RESEARCH
    93. Kern, W; Braess, J; Bottger, B; Kaufmann, CC; Hiddemann, W; Schleyer, E
      Oxaliplatin pharmacokinetics during a four-hour infusion

      CLINICAL CANCER RESEARCH
    94. Maindrault-Goebel, F; Louvet, C; Andre, T; Carola, E; Lotz, JP; Molitor, JL; Garcia, ML; Gilles-Amar, V; Izrael, V; Krulik, M; de Gramont, A
      Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)

      EUROPEAN JOURNAL OF CANCER
    95. Andre, T; Louvet, C; Maindrault-Goebel, F; Couteau, C; Mabro, M; Lotz, JP; Gilles-Amar, V; Krulik, M; Carola, E; Izrael, V; de Gramont, A
      CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer

      EUROPEAN JOURNAL OF CANCER
    96. Matsui, SI; Endo, W; Wrzosek, C; Haridas, K; Seetharamulu, P; Hausheer, FH; Rustum, YM
      Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: Mechanisms and clinical implications

      EUROPEAN JOURNAL OF CANCER
    97. Bleiberg, H
      CPT-11 in gastrointestinal cancer

      EUROPEAN JOURNAL OF CANCER
    98. Joulia, JM; Pinguet, F; Ychou, M; Duffour, J; Astre, C; Bressolle, F
      Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid

      EUROPEAN JOURNAL OF CANCER
    99. Iveson, TJ; Hickish, T; Schmitt, C; Van Cutsem, E
      Irinotecan in second-line treatment of metastatic colorectal cancer: Improved survival and cost-effect compared with infusional 5-FU

      EUROPEAN JOURNAL OF CANCER
    100. Jackman, AL; Kimbel, R; Ford, HER
      Combination of raltitrexed with other cytotoxic agents: Rationale and preclinical observations

      EUROPEAN JOURNAL OF CANCER


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/10/20 alle ore 16:33:35